In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

ESC Clinical Practice Guidelines

Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, there have been several randomized controlled trials that should change patient management ahead of the next scheduled full guideline. This 2023 Focused Update addresses changes in recommendations for the treatment of HF because of this new evidence. We considered new, published evidence up until the 31 March 2023. After considering and discussing many new  major randomized controlled clinical trials and meta-analyses, the Task Force voted to include those that would lead to Class IIa and I recommendations. This has led to us updating some of our guidance for the treatment of HFmrEF, HFpEF, comorbidities and Acute HF.

Chronic Heart Failure
Acute Heart Failure
Heart Failure

Main resources

Scientific Presentation at ESC Congress 2023

Access the live session and the replay

Watch now

More resources

ESC TV Interview

The essentials of the Guidelines in just a few minutes.

Congress News Article

Insights from the Chairs of the Guidelines Task Force.

ESC Pocket Guidelines App

Have the ESC Pocket Guidelines with you all the time.

Download for free